T细胞亚群在重型再生障碍性贫血治疗中的疗效预测价值

唐旭东; 张姗姗; 许勇钢; 杨晓红; 李柳; 刘锋; 麻柔

doi:10.13288/j.11-2166/r.2013.20.026

您当前的位置：

首页 >

文章列表页 >

T细胞亚群在重型再生障碍性贫血治疗中的疗效预测价值

临床研究 | 更新时间：2021-11-17

- T细胞亚群在重型再生障碍性贫血治疗中的疗效预测价值
- Efficacy Prediction of T cell Subsets in Kidney-Supplementing Medicinal Combined with Anti-Lymphocyte Globulin/Anti-Thymocyte Globulin for Severe Aplastic Anemia
- 中医杂志 2013年54卷第20期页码：1755-1758
- 作者机构：
  
  中国中医科学院西苑医院
- 作者简介：
- 基金信息：
- DOI：10.13288/j.11-2166/r.2013.20.026
  中图分类号： R556
- 纸质出版：2013
- 稿件说明：
移动端阅览
[1]唐旭东,张姗姗,许勇钢,杨晓红,李柳,刘锋,麻柔.T细胞亚群在重型再生障碍性贫血治疗中的疗效预测价值[J].中医杂志,2013,54(20):1755-1758.

TANG Xudong, ZHANG Shanshan, XU Yonggang, et al. Efficacy Prediction of T cell Subsets in Kidney-Supplementing Medicinal Combined with Anti-Lymphocyte Globulin/Anti-Thymocyte Globulin for Severe Aplastic Anemia[J]. Journal of Traditional Chinese Medicine2013, 54(20): 1755-1758.
[1]唐旭东,张姗姗,许勇钢,杨晓红,李柳,刘锋,麻柔.T细胞亚群在重型再生障碍性贫血治疗中的疗效预测价值[J].中医杂志,2013,54(20):1755-1758. DOI： 10.13288/j.11-2166/r.2013.20.026.

TANG Xudong, ZHANG Shanshan, XU Yonggang, et al. Efficacy Prediction of T cell Subsets in Kidney-Supplementing Medicinal Combined with Anti-Lymphocyte Globulin/Anti-Thymocyte Globulin for Severe Aplastic Anemia[J]. Journal of Traditional Chinese Medicine2013, 54(20): 1755-1758. DOI： 10.13288/j.11-2166/r.2013.20.026.

摘要

目的探讨CD3+HLA-DR+T和CD3+CD25+T细胞亚群在以补肾中药联合抗淋巴细胞球蛋白/抗胸腺细胞球蛋白（ALG/ATG）为主治疗重型再生障碍性贫血（简称重型再障）中的疗效预测价值。方法采用补肾中药联合ALG/ATG对71例重型再障患者进行治疗

辅以环孢菌素A、雄激素、造血生长因子等

检查重型再障患者治疗前后CD3+HLA-DR+T和CD3+CD25+T细胞亚群的免疫学指标变化。结果重型再障经补肾中药联合ATG/ALG治疗后

有效患者（59例）的CD3+CD25+T较无效患者（12例）明显升高（P<0.05）

CD3+HLA-DR+T、CD3+HLA-DR+T/CD3+CD25+T与重型再障的疗效无明显相关性（P>0.05）。经过Kaplan-Meier过程

CD3+HLA-DR+T细胞比例>7%时

CD3+CD25+T细胞比例>3%时

CD3+HLA-DR+T/CD3+CD25+T细胞≤2.5时患者生存期较长（P<0.05）。结论 CD3+CD25+T可作为重型再障疗效预测性指标

其升高提示疗效较佳;CD3+HLA-DR+T细胞比例>7%、CD3+CD25+T细胞比例>3%、CD3+HLA-DR+T/CD3+CD25+T细胞≤2.5提示预后较好

生存期较长。

Abstract

Objective To study the efficacy prediction of CD3+HLA-DR+T and CD3+CD25+T cell subsets in kidneysupplementing medicinal combined with anti-lymphocyte globulin/anti-thymocyte globulin（ALG/ATG）for severe aplastic anemia（SAA）.Methods Totally 71cases of SAA were given the combo therapy of kidney-supplementing medicinal

ALG/ ATG

Cyclosporin A

androgens and hematopoietic growth factors.The percentages of CD3+HLA-DR+T and CD3+CD25+T were detected before and after treatment.Results The percentage of CD3+CD25+T was significantly increased in the effective cases after treatment（P<0.05）.There was no significant difference between the therapeutic effect and the percentage of CD3+HLA-DR+T and CD3+HLA-DR+T/CD3+CD25+T（P>0.05）.The survival was prolonged when the percentage of CD3+HLA-DR+T exceeded 7%（P<0.05）

the percentage of CD3+CD25+T exceeded 3%（P<0.05）and CD3+HLA-DR+ T/CD3+CD25+T was less than or equal to 2.5（P<0.05）after Kaplan-Meier procedure.Conclusion The percentage of CD3+CD25+T can be taken as the indicator of efficacy prediction and its exaltation suggests a better efficacy.The survival is prolonged when the percentage of CD3+HLA-DR+T exceeds 7%

the percentage of CD3+CD25+T exceeds 3% and CD3+ HLA-DR+T/CD3+CD25+T is less than or equal to 2.5.

关键词

Keywords

references

查看原文

浏览量

301

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

基于“肾欲坚，急食苦以坚之，用苦补之”探讨绝经后骨质疏松症的防治

补肾益精对老年脑功能的临床研究

补肾复方为主治疗肾阳虚型再生障碍性贫血30例临床观察

健脾补肾中药对慢性肾衰血透患者细胞免疫功能的影响

补肾化瘀法对再生障碍性贫血骨髓细胞酶学指标的影响